Nurix presents the discovery and chemical structure of first-in-class cbl-b inhibitor nx-1607 at the american chemical society (acs) meeting
Presentation highlights nurix's innovation and leadership in targeted protein modulation, including ligase inhibition unique mechanism of action, an intramolecular glue, locks the e3 ligase casitas b-lineage lymphoma proto-oncogene b (cbl-b) in a closed inactive state phase 1 trial ongoing as monotherapy and in combination with paclitaxel in patients with a range of oncology indications san francisco, march 20, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today disclosed the discovery and structure of nx-1607 in the first time disclosures session at the american chemical society spring 2024 meeting in new orleans, la. this is the first inhibitor of cbl-b to advance into clinical studies and a prime example of nurix's ability to target previously undruggable e3 ligases.
NRIX Ratings Summary
NRIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission